HBME-1

This antibody reacts with an antigen present in the membrane of mesothelial cells, having been raised against mesothelioma cell line SPC111. The target epitope is located in microvilli.

Immunohistochemical expression

normal thyroid

negative

nodular goitre

0/10 positive

follicular adenoma

3/253 positive

oxyphilic cell adenoma

7/46 positive

follicular carcinoma

19/36 positive

papillary carcinoma

80/90 positive

Diagnostic utility

 

adenocarcinoma

mesothelioma

Miettinen 199524

174/280

25/29

Renshaw 1995

17/20

20/20

Attanoos 19965

23/32

26/42

Savera 1996

77/140

19/21

Ascoli 19976

24%

100%

Bateman 19977

10/14

17/17

Dejmek 19978

11/43

78/110

Donna 19979

6/42

71/84

Kennedy 199710

27/63

53/57

Ordonez 199711

14/22

16/20

Riera 199712

83/211

45/57

Wilson 199725

5/9

12/21

Chenard-Neu 199813

9/30

25/28

Fetsch 1998 (on cytological specimens)14

28/43

34/38

Ordonez 199815

40/45

31/35

Oates 200016

20/42

20/40

Brockstedt 20004

20/57

91/119

Kayser 200117

24/146

101/118

Harper 200118

10/18

74/112

Gonzalez-Lois 200119

2/23

40/44

Comin 200120

23/23

41/42

Roberts 200126

10/18

75/112

Miettinen 200128

not studied

20/30

Ordonez 200327

34/50

51/60

Overall

49% (667/1371)

78% (985/1256)

A systematic review of fourteen studies (consisting of 769 epithelioid mesotheliomas and 676 pulmonary adenocarcinomas) reported sensitivities and specificities of HBME-1 for epithelioid mesothelioma of 85% and 43%29.

The staining pattern is said to be different in mesotheliomas (which have a thick, "bushy", membrane pattern) from adenocarcinomas (which have a thin membrane or a cytoplasmic staining pattern)14,20. Others5,10 consider that the patterns are not distinct and that the antibody is of little value in the differential diagnosis21. Staining is reportedly stronger in post mortem specimens that in the corresponding ante mortem specimens22.

References

1 Miettinen, M., Karkkainen, P. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours. Virchows Arch 1996;429:213-9.

2 Sack, M. J., Astengo-Osuna, C., , Lin, B. T., Battifora, H., LiVolsi, V. A. HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol 1997;10:668-74.

3 Battifora H, HBME-1 in thyroid neoplasms in Immunohistochemistry Long Course, Nice, October 18-23, 1998.

4 Brockstedt U, Gulyas M, Dobra K. An optimized batter of eight antibodies that can distingusih most cases of epithelial mesothelioma form adenocarcinoma. Am J Clin Pathol 2000;114:203-9.

5 Attanoos, R. L., Goddard, H., Gibbs, A. R. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma. Histopathology 1996;29:209-15.

6 Ascoli, V., Carnovale-Scalzo, C., Taccogna, S., Nardi, F. Utility of HBME-1 immunostaining in serous effusions. Cytopathology 1997;8:328-35.

7 Bateman, A. C., al-Talib, R. K., Newman, T., Williams, J. H., Herbert, A. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Histopathology 1997;30:49-56.

8 Dejmek, A., Brockstedt, U., Hjerpe, A. Optimization of a battery using nine immunocytochemical variables for distinguishing between epithelial mesothelioma and adenocarcinoma. Apmis 1997;105:889-94.

9 Donna, A., Betta, P. G., Chiodera, P. et al. Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1. Hum Pathol 1997;28:929-37.

10 Kennedy, A. D., King, G., Kerr, K. M. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. J Clin Pathol 1997;50:859-62.

11 Ordonez, N. G.The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Am J Surg Pathol 1997;21:1399-408.

12 Riera, J. R.Astengo-Osuna, C.Longmate, J. A. Battifora, H. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Am J Surg Path 1997;21:1409-19.

13 Chenard-Neu, M. P., Kabou, A., Mechine, A., et al. [Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies]. an Pathol 1998;18:460-5.

14 Fetsch, P. A., Abati, A., Hijazi, Y. M. Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer 1998;84:101-8.

15 Ordonez, N. G. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998;22:1203-14.

16 Oates, J., Edwards, C., HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000;36:341-7.

17 K Kayser et al. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients. J Pathol 2001;193:175-180.

18 Harper CM. Evaluation of a commercially available immunohistochemical diagnostic panel for malignant mesothelioma. J Pathol 2001:193(suppl):39A.

19 Gonzalez-Lois, C., Ballestin, C., Sotelo, M. T., Lopez-Rios, F., Garcia-Prats, M. D., Villena, V. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathology 2001;38:528-34.

20 Comin, C. E., Novelli, L., Boddi, V., Paglierani, M., Dini, S. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Hum Pathol 2001;32:529-536.

21 Ordonez, N. G. The immunohistochemical diagnosis of epithelial mesothelioma. Human Pathol 1999;30:313-323.

22 Roberts, F., McCall, A. E., Burnett, R. A. Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry. J Clin Pathol 2001;54:766-70.

23 Abutaily, A.S., Addis, B.J. and Roche, W.R. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol 2002;55:662-8.

24 Miettinen M, Kovatich AJ. HBME-1: a monoclonal antibody usful in the differential diagnosis of mesothelioma,k adenocarcinoma and soft tissue and bone tumors. Appl Immunohistochem 1995;3:115-122.

25 Wilson JD, Merino MJ, Harris C et al. Mesothelioma vs adenocarcinoma; does immunohistochemistry help? Lab Invest 1997;76:174A.

26 Roberts, F., C. M. Harper, et al. (2001). "Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies." Am J Clin Pathol 116(2): 253-62.

27 Ordonez, N. G. (2003). "The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma." Am J Surg Pathol 27(8): 1031-51.

28 Miettinen, M., J. Limon, et al. (2001). "Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma." Am J Surg Pathol 25(5): 610-7.

29 King JE, Thatcher N, Pickering CA, et al. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006; 48:223-32

 

This page last revised 16.2.2006.

©SMUHT/PW Bishop